Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-138
Tabersonine
Cat. No.
AKA-138
CAS No.
4429-63-4
MF
C21H24N2O2
MW
336.42746
Tabersonine is a selective NLRP3 inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
Tabersonine
CAS No.
4429-63-4
MF
C21H24N2O2
MW
336.42746
Specification
98%
Description
Tabersonine is a selective NLRP3 inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In Stock
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Zhang D, et al. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination. Biochemical Pharmacology. 2018 Aug;154:183-192.
[2]. Li X, et al. Tabersonine Induces the Apoptosis of Human Hepatocellular Carcinoma In vitro and In vivo. Anti-cancer Agents in Medicinal Chemistry. 2024;24(10):764-772.
[3]. Xu HW, et al. Tabersonine, a natural NLRP3 inhibitor, suppresses inflammasome activation in macrophages and attenuate NLRP3-driven diseases in mice. Acta Pharmacologica Sinica. 2023 Jun;44(6):1252-1261.
[2]. Li X, et al. Tabersonine Induces the Apoptosis of Human Hepatocellular Carcinoma In vitro and In vivo. Anti-cancer Agents in Medicinal Chemistry. 2024;24(10):764-772.
[3]. Xu HW, et al. Tabersonine, a natural NLRP3 inhibitor, suppresses inflammasome activation in macrophages and attenuate NLRP3-driven diseases in mice. Acta Pharmacologica Sinica. 2023 Jun;44(6):1252-1261.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-373
Abietic acid
CAS No.:514-10-3
MF:C20H30O2
AKA-372
Dipexion™ Fmoc-Val-Ser(psi(Me,Me)pro)-OH
CAS No.:186023-49-4
MF:C26H30N2O6
AKA-371
Dipexion™ Fmoc-Gly-Ser(psi(Me,Me)pro)-OH
CAS No.:1095952-22-9
MF:C23H24N2O6
AKA-370
Oxymatrine
CAS No.:16837-52-8
MF:C15H24N2O2
AKA-369
Matrine
CAS No.:519-02-8
MF:C15H24N2O
AKA-368
Dipexion™ Fmoc-Lys（Boc）-Thr[PSI(Me,Me)Pro]-OH
CAS No.:911838-56-7
MF:C33H43N3O8
AKA-367
Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH
CAS No.:339531-50-9
MF:C27H32N2O6
AKA-366
Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH
CAS No.:1266350-99-5
MF:C29H36N2O7
AKA-365
Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH
CAS No.:957780-56-2
MF:C31H38N2O8
AKA-364
Dipexion™ Fmoc-Lys（Boc）-Ser[PSI(Me,Me)Pro]-OH
CAS No.:957780-54-0
MF:C32H41N3O8
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
